Participants 42 133 4
employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo
Participants 316 373 4
in employed patients with major depressive disorder (MDD)
Participants 383 562 7
Gainfully employed (≥20 h/wk) male and female outpatients with MDD were randomly assigned (2:1 ratio) to 12 weeks of double-blind treatment with desvenlafaxine 50 mg/d or placeb
Participants 841 957 3
tion. A predefined, modified ITT population (ie, those in the ITT population with baseline HAM-D₁₇ ≥20) was al
Participants 1849 1881 3
as efficacious for treating MDD 
